What medication-assisted treatment (mat) actually looks like

Medication-Assisted Treatment combines FDA-approved medications — such as buprenorphine (Suboxone), methadone, or naltrexone (Vivitrol) — with counseling and behavioral therapies. MAT is clinically proven to reduce opioid use, prevent overdose deaths, decrease criminal activity, and improve treatment retention.

Clinical placement into medication-assisted treatment (mat) follows the ASAM Criteria, a six-dimension assessment used by virtually every licensed program in the US. The framework evaluates withdrawal risk, medical complications, emotional/behavioral conditions, readiness to change, relapse potential, and recovery environment. A placement specialist (or admitting clinician) scores each dimension and matches the patient to the appropriate medical detox, residential, IOP, outpatient, or MAT program.

What insurance covers

Under the federal MHPAEA parity law, commercial plans must cover medication-assisted treatment (mat) at parity with medical care. That means same copays, same deductible rules, same pre-authorization requirements as any other medical procedure. Most medication-assisted treatment (mat) admissions involve a deductible ($0–$2,000 typically), then 10–40% coinsurance. Medicaid coverage varies by state — residents of Medicaid-expansion states have broader access. Our directory filters all 21,568 SAMHSA-verified centers by carrier.

Evidence base & outcomes

Per NIDA’s research-based principles, effective treatment combines clinical therapy (cognitive-behavioral therapy, motivational interviewing, contingency management) with FDA-approved medications where applicable, plus structured aftercare. Programs lasting 90+ days produce materially better outcomes than shorter stays. For opioid and alcohol use disorders, MAT combined with therapy outperforms therapy alone by 2–3× on 12-month sobriety measures.